TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review

Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer

(2020) Marie Muller et al.   United European Gastroenterology Journal

Crohn’s disease

(2020) Giulia Roda et al.   Nature Reviews Disease Primers

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy

(2019) Julián Panés et al.   Journal of Crohns & Colitis

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease

(2019) Guillaume Bouguen et al.   Clinical Gastroenterology and Hepatology

Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study

(2019) Akbar K Waljee et al.   Lancet Gastroenterology & Hepatology

Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry

(2018) Geert D’Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses—Part I

(2018) Simon R Knowles et al.   INFLAMMATORY BOWEL DISEASES

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

(2018) Gary R Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Malignancies in Inflammatory Bowel Disease

(2018) Sylvie Scharl et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents

(2016) Jordan Axelrad et al.   Clinical Gastroenterology and Hepatology

Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis

(2016) Stefanos Bonovas et al.   Clinical Gastroenterology and Hepatology

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics

(2015) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Incidence, Management, and Course of Cancer in Patients with Inflammatory Bowel Disease

(2015) A. Algaba et al.   Journal of Crohns & Colitis

Biologic agents for IBD: practical insights

(2015) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

(2015) Enayatullah Baki et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease

(2014) C. J. M. Williams et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Biological Agents for Moderately to Severely Active Ulcerative Colitis

(2014) Silvio Danese et al.   ANNALS OF INTERNAL MEDICINE

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

(2014) Nynne Nyboe Andersen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies

(2014) Florian Beigel et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A tale of two diseases: The history of inflammatory bowel disease

(2013) Daniel J. Mulder et al.   Journal of Crohns & Colitis

Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies

(2012) Tine Jess et al.   Clinical Gastroenterology and Hepatology

Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009

(2012) Jennifer L. Seminerio et al.   DIGESTIVE DISEASES AND SCIENCES

Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease

(2011) Lisa J Herrinton et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Safety of infliximab in 10 years of clinical practice

(2011) Sarah OʼDonnell et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

(2010) Mario Cottone et al.   Clinical Gastroenterology and Hepatology

Safety of infliximab in Crohnʼs disease

(2010) H. Hamzaoglu et al.   INFLAMMATORY BOWEL DISEASES

Cancer in Crohnʼs Disease patients treated with infliximab: A long-term multicenter matched pair study

(2010) Livia Biancone et al.   INFLAMMATORY BOWEL DISEASES

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

(2009) Y. ZABANA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

(2008) C. W. LEES et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008)

(2008) G. T. HO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England

(2008) E. A. RUSSO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serious Events with Infliximab in Patients with Inflammatory Bowel Disease

(2008) Hilbert S de Vries et al.   DRUG SAFETY

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT